Flow cytometry and in vitro experiments were utilized to explore the changes of the proportion of T cell subtypes elicited after treatment of DLBCL, and the target roles of PD1 and LAG3 during the treatment. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.